Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- S-4 Registration of securities issued in business combination transactions
- 3.2 Form of Certificate of Incorporation of the Combined Entity (Attached to the Proxy Statement/prospectus Which Forms a Part of This Registration Statement As Annex B)
- 3.4 Form of Bylaws of the Combined Entity (Attached to the Proxy Statement/prospectus Which Forms a Part of This Registration Statement As Annex C)
- 23.1 Consent of Marcum LLP, Independent Registered Public Accounting Firm of Larkspur Health Acquisition Corp.
- 23.2 Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm of Zyversa Therapeutics, Inc.
- 99.6 Consent of Cassel Salpeter & Co., LLC (Attached to the Proxy Statement/prospectus Which Forms a Part of This Registration Statement As Annex G)
- EX-FILING FEES Filing Fee Table
- Download Excel data file
- View Excel data file
Associated filings
- 15 Nov 22 EFFECT Notice of effectiveness
- 14 Nov 22 424B3 Prospectus supplement
- 3 Nov 22 S-4/A Registration of securities issued in business combination transactions (amended)
- 20 Oct 22 S-4/A Registration of securities issued in business combination transactions (amended)
- 27 Sep 22 S-4/A Registration of securities issued in business combination transactions (amended)
-
12 Aug 22 S-4 Registration of securities issued in business combination transactions
ZVSA similar filings
- 3 Nov 22 Registration of securities issued in business combination transactions (amended)
- 20 Oct 22 Registration of securities issued in business combination transactions (amended)
- 27 Sep 22 Registration of securities issued in business combination transactions (amended)
- 12 Aug 22 Registration of securities issued in business combination transactions
Filing view
External links
Exhibit 23.2
Consent of Independent Registered Public Accounting Firm
We consent to the reference to our firm under the caption "Experts" and to the use of our report dated April 8, 2022, with respect to the financial statements of ZyVersa Therapeutics, Inc. included in the Proxy Statement of Larkspur Health Acquisition Corp. that is made a part of the Registration Statement (Form S-4) and related Prospectus of Larkspur Health Acquisition Corp. for the registration of 9,200,000 shares of its common stock.
/s/ Ernst & Young LLP
Miami, Florida
August 12, 2022